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Abstract:
It is well established that African Americans exhibit higher incidence, higher mortality, and more
aggressive forms of some cancers, including those of breast, prostate, colon, stomach, and
cervix. Here we examine the ancestral haplotype of the TRPV6 calcium channel as a putative
genomic factor in this racial divide. The minor (ancestral) allele frequency is 60% in people of
African ancestry, but between 1 and 11% in all other populations. Research on TRPV6
structure/function, its association with specific cancers, and the evolutionary-ecological
conditions which impacted selection of its haplotypes are synthesized to provide evidence for
TRPV6 as a germline susceptibility locus in cancer. Recently elucidated mechanisms of TRPV6
channel deactivation are discussed in relation to the location of the allele favored in selection,
suggesting a reduced capacity to inactivate the channel in those who have the ancestral
haplotype. This could result in an excessively high cellular Ca2+, which has been implicated in
cancer, for those in settings where calcium intake is far higher than in their ancestral
environment. A recent report associating increasing calcium intake with a pattern of increase in
aggressive prostate cancer in African-American but not European-American men may be related.
If TRPV6 is found to be associated with cancer, further research would be warranted to improve
risk assessment and examine interventions with the aim of improving cancer outcomes for
people of African ancestry.

Figure 1:
Proportion of AA and EA cases having NCCN high risk prostate cancer (%) vs. calcium intake.
The proportion of AA cases with high risk prostate cancer displays a pattern of increase with
total calcium intake for AA men. Multiethnic study of 1,657 cases and 1,657 controls. Study by
K. Batai et al. https://creativecommons.org/licenses/by/4.0/ Figure reformatted.

Racial disparities in cancer
African Americans (AAs) are residents of the United States of America, typically with an
admixture of Sub-Saharan African and European ancestry [1]. The disparity in cancer outcomes
between AAs and Americans of European ancestry (EAs) has been a cause for concern in recent
years. Centers for Disease Control and Prevention age-adjusted death rates per 100,000 for AAs
from prostate cancer (14.3) indicate mortality twice as high as for EAs (7.4). The breast cancer
death rate for AAs (16.4) is high compared with that of EAs (11.1) [2] and they exhibit twice the
proportion of triple negative breast cancer, which is more aggressive, more deadly, and typically
strikes women of younger age than other molecular subtypes. Colorectal cancer mortality in AAs
(18.9) is alarmingly high compared with that of EAs (13.8). and pancreatic cancer is also
disproportionately higher (13.3) than in EAs (10.9) [2]. In these cancers TRPV6 is upregulated –
highly so for breast and prostate cancers, where TRPV6 inhibition is under study as a potential
therapeutic strategy. In prostate cancer, TRPV6 expression level has been linked to tumor
progression and has been proposed as a prognostic marker [3].

Non-genomic factors in racial disparity
It has been suggested that a combination of factors including social determinants of health,
access to health care, biological factors including genomics, and patterns of research lead to
racial disparities in cancer outcomes [4]. Socioeconomic factors that impact health include
education status, level of insurance, access to medical care. Factors rooted in stressors such as
childhood trauma and also historical and societal inequalities that impact attitudes regarding
medical care are implicated. Furthermore, therapies and guidelines are typically based on
research that is overwhelmingly conducted on subjects of European descent. This has led to a
recent call to address health disparities through the redesign of clinical trials [5].
Culturally influenced factors such as exercise, lifestyle and diet are also under study. Recently,
Batai et al (Kittles lab) investigated the association of calcium and vitamin D intake with prostate
cancer in a study of a multiethnic group of 1,657 cases and 1,657controls [6]. The proportion of
cases diagnosed with aggressive prostate cancer (as determined using the National
Comprehensive Cancer Network (NCCN) risk stratification scheme) was found to increase with
increasing total calcium intake in AA men but not in EA men (See figure 1). Also, in AA men
there was an inverse relationship between vitamin D intake and prostate cancer that was not seen
in EA men.

Search for genomic factors in racial disparity
Possible hereditary factors in the higher cancer burden observed in AAs are confounded by
socioeconomic and cultural factors, such as those discussed above, that impact health and access
to care. Studies that normalize socioeconomic factors still detect racial disparities, providing
evidence that genomic factors, possibly in interaction with environmental factors [5], for
example calcium intake, may impact cancer burden.
However, discovery of genomic factors in racial cancer disparities is greatly hampered by racial
disparities in genome-wide association studies (GWAS), from which such associations are
typically inferred. People of African ancestry continue to be vastly under-represented in GWAS.
As recently as 2009, 96% of GWAS samples were conducted on subjects of European descent.
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The subsequent 7 years saw a rise in GWAS samples from Asian populations, however, less than
4% of all samples analyzed were from subjects of either African or Latino ancestry [7].
When conclusions are drawn from such studies, they may not be pertinent to AAs. We are aware
of only one study that aimed to investigate the association of TRPV6 with prostate cancer
progression, and the finding was that TRPV6 alleles do not influence prostate cancer progression
[8]. However, the study included only Caucasians as controls; case samples were 11.3%
heterozygous; only 1 sample (0.7%) was homozygous for the ancestral allele. Arguably, the
study did not have the statistical power to detect an association if it is specific to the ancestral
haplotype.
Attempts have been made to elucidate genomic underpinnings of racial disparities in cancer,
however, a genomic explanation remains elusive. Some studies have investigated germline
susceptibility loci that were previously implicated in specific cancers of subjects who were
predominantly EAs [9], finding some that are and some that are not also implicated in cancer of
AAs. However, most breast and prostate cancer GWAS hits have not been replicated in people
of African descent. Some whole-genome investigations of germline variants for association with
cancer in AAs have been conducted from an agnostic viewpoint, without preselecting the single
nucleotide polymorphisms (SNPs) under investigation [10]. The statistical power of such studies
is generally sufficient to detect large effect sizes, and TRPV6 has not been implicated.
Approaches such as admixture mapping have been used to narrow the field of germline
candidates. Mutation profiling has been undertaken to investigate exclusively somatic variants in
breast cancer samples. To our knowledge, however, an investigation of association between the
germline TRPV6 and cancer in subjects of African ancestry has not been conducted.
Recently, the African American Breast Cancer Epidemiology and Risk (AMBER) [11] and
African Ancestry Prostate Cancer GWAS (AAPC) [10] Consortiums were created to conduct
studies with greater statistical power to detect genomic and environmental factors that are
specific to AAs. The AMBER consortium has produced a dataset to investigate breast cancer in
AAs by combining biospecimens from 7,500 AA cases and 17,000 healthy controls. This
consortium has investigated germline microRNAs, rare exome variants, specific genes, and
pathways, preferential linkage disequilibrium and admixture associated regions for association
with breast cancer in AAs. The AAPC consortium has produced a dataset to investigate prostate
cancer in AAs that currently contains over 10,000 cases and 10,000 controls [12] It has
conducted genome-wide association meta-analyses, and studies of specific regions. The
H3Africa Consortium [13] and RESPOND study are newer initiatives. The latter, with over
20,000 cases, is currently recruiting AA men with prostate cancer [14]. These consortiums are
widely expected to contribute further to understanding of genomic factors influencing racial
disparity in breast and prostate cancers [15]. Neither consortium has yet, to our knowledge,
investigated the TRPV6 region (7q34-35) specifically.

M681T identified as carrier of the favored allele in positive selection
The TRPV6 haplotype is a coupled polymorphism consisting of three nonsynonymous SNPs
(C157R, M378 V and M681T) in humans on chromosome 7q34. Accelerated evolution is
demonstrated for the TRPV6 protein, but only in this region [16]. The ancestral allele is in this
case the minor allele. It has a frequency of 60% in people of African ancestry but is between 1
and 11% in all other populations listed in 1000 Genomes [17]. All non-African populations carry
2

a signature of selection on the derived haplotype and their nucleotide diversity is an order of
magnitude lower than those of African populations [16]. This and other evidence supports the
hypothesis that the derived haplotype results from widespread parallel selection acting on a
genetic variation present in the ancestral African populations that became fixed in a soft sweep
[18]. In a hard sweep, a population adapts to an environmental change through a new
advantageous mutation. In a soft sweep, however, adaptation arises from standing genetic
variation that pre-exists in the population. The derived haplotype results in a protein variant that
is thought to have conferred evolutionary advantage and become fixed in populations outside of
Africa about 7-10,000 years ago [19]. It is the M681T SNP of this haplotype that is
hypothesized as the carrier of the favored allele in positive selection [19]. This has been
confirmed by recent research [20], suggesting that differences between the ancestral and derived
protein variants coded by this region impact function and confer evolutionary advantage in nonAfrican populations.

TRPV6, calcium, and cancer
TRPV6 and its closest relative, TRPV5, with which it shares 75% amino acid identity, are genes
that code for calcium channels in epithelial cells [3] such as in breast, prostate, colon, lung and
pancreas. These proteins permit and regulate calcium (Ca2+) entry into these cells. They are also
important in Ca2+ homeostasis, with TRPV6 facilitating Ca2+ absorption in the intestines and
TRPV5 involved in Ca2+ reabsorption in the kidneys [21].
Intracellular (ie: cytosolic) Ca2+ concentration is typically prevented from reaching toxic levels
by a feedback inhibition mechanism that inactivates the TRPV6 Ca2+ channel. In contrast, Ca2+
level in extracellular fluids, including blood, is much higher [3]. Ca2+ signaling is central to
many cellular processes, including balanced cell proliferation, cell motility, and apoptosis.
Remodeling of this signaling and the attendant changes in Ca2+ concentration have been
implicated in cancer [22]. Carcinomas, which are cancers originating from epithelial cells,
characteristically exhibit altered Ca homeostasis [3]. Research has revealed upregulation of
TRPV6 in some carcinomas, particularly of the prostate, breast, colon and pancreatic: cancers
from which AAs suffer higher mortality. It has been proposed that people with the ancestral
haplotype may have dysregulated Ca2+ homeostasis when their calcium consumptions is far
higher than in the ancestral environment [23].
M681T located in region of Ca2+-dependent inactivation of TRPV6 channel
Investigations into the structure and function of TRPV5 and TRPV6 have described channel
gating mechanisms, mediated by a calmodulin (CaM) ligand, whereby Ca2+ may enter the cell
(open channel) or is blocked by closure of the channel [24], [25]. Mutation of a key residue in
the gating region induced cell death due to Ca2+ overload [26], highlighting the importance of the
inactivation mechanism to health. Calmodulin (CaM) binding enables the TRPV6 channel to be
in an open state, but subject to fast inactivation by a Ca2+ feedback mechanism [24].
Recent research places M681T, the allele favored in selection, in the region of influence over the
CaM binding that is necessary for the TRPV6 protein to inactivate the channel, protecting the
cell from Ca2+ overload. Structural studies of TRPV6 place M681T at a distance of 5 amino
acids from a key CaM interface region [24]. Additionally, new research has extended the region
of influence on CaM binding to include M681T [25].
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Hughes et al investigated TRPV6 channel function in derived vs. ancestral TRPV6 protein
variants that were cloned into expression vectors and transfected into a human cell line. The
percentage drop in Ca2+ current density was measured when Ca2+ extracellular concentration
became high and activated gate closure. The channel of the derived variant exhibited a greater
(48.9 +/− 5%) drop in Ca2+ current density than the ancestral (34.9 +/− 6%). This difference was
not statistically significant (p = 0.09) at alpha cutoff of 0.05. However, due to the importance of
the M681T region to CaM binding, the authors suggested that the difference in channel
inactivation could be biologically relevant, and the derived allele more sensitive to Ca2+ feedback
[19].
An evolutionary-ecological model
The typical admixture in AAs is approximately 75% Niger-Kordofanian West African and 25%
Northern European genetic ancestry [23]. It has been postulated that TRPV6 sequence variation
among populations may have been influenced by domestication of milk-producing animals,
beginning ∼10 000 years ago [27]. The dairy farming that swept through Europe, parts of Africa,
and much of the rest of the world did not take hold in West Africa due to the tsetse fly, thus
calcium consumption in this region remained low (~200–400 mg per day) [28]. Surprisingly,
West Africans do not develop osteoporosis, as do East Africans and others from dairy farming
regions characterized by far higher calcium consumption [29]. It is thought that the TRPV5 and
TRPV6 ancestral haplotypes play a role in greater Ca2+ absorption and reabsorption, explaining
higher bone density in populations of West African descent [19].
Although not as high as the AAs who share much of their ancestry, high prevalence of prostate
cancer has also been found in West African men [30]. It has been recently hypothesized by
Hilliard [23] that the TRPV6 ancestral haplotype plays a role in both high bone density and the
racial cancer disparity in AAs and others of West African descent. While conferring advantage in
calcium-poor ancestral environments, this haplotype may be maladaptive in the US and other
regions where calcium dietary and supplemental intake is far higher.

Synthesis of research
People of African descent suffer worse outcomes from common carcinomas in which TRPV6 is
upregulated. The ancestral allele for the TRPV6 epithelial CA channel has a frequency of 60% in
people of African ancestry, yet all non-African populations carry a signature of selection on the
derived haplotype. The West African environment, rare in that the derived allele was not
selected, was and remains to some extent a calcium-poor environment, yet West Africans do not
develop osteoporosis. The association of ancestral TRPV6 and TRPV5 with higher calcium
absorption and reabsorption has been previously established. However, an explanatory
mechanism for evolutionary advantage of the allele that is thought to be the target of selection in
evolution (M681T) is not agreed upon.
Recent research supports a hypothesis that translation of the derived transcript results in TRPV6
protein structure that blocks the passage of Ca2+ into the cell when cytosolic levels become
excessively high, while the ancestral variant of the protein may not as effectively protect the cell
from Ca2+ overload. M681T is in close proximity to an important binding site in TRPV6-CaM
inactivation of the Ca2+ channel. The deactivation region of the TRPV6 channel has not itself
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been resolved by x-ray crystallography. However, atomic-resolution of other regions and related
structures [25], along with biophysical techniques have been used to investigate channel
deactivation, implicating the M681T region as crucial to the channel deactivation that is required
to protect the cell from Ca2+ overload when plasma levels become too high.
The above evidence, taken together with Batai et al research associating increasing Ca2+ intake
with a pattern of increase in aggressive prostate cancer in AA men leads us to hypothesize a
mechanism for Hilliard’s evolutionary-ecological model: that when calcium consumption is
high, binding differences in the M681T region of the ancestral TRPV6 haplotype do not as
effectively inactivate the epithelial Ca2+ channel, leading to dysregulation of Ca2+ homeostasis.
This could potentially worsen outcomes for carcinomas of the prostate, breast, and colon.
Investigation of the TRPV6 ancestral haplotype as a germline susceptibility locus in cancer, both
as main effect and in interaction with TRPV5 and with calcium consumption, could lead to
actionable discoveries including preventive lifestyle changes for people having the ancestral
allele.

Future Directions:
Racial disparities in cancer present a serious problem, and an opportunity for the research
community to improve cancer outcomes for people of African ancestry. Addressing genomic
factors along with patterns of care is expected to have a positive impact. A research challenge
will be to uncover genomic underpinnings of the disparity, including complex factors such as
epistatic effects. This could lead to inclusion of implicated SNPs in hereditary cancer screens
designed to be relevant to people of African descent. Additionally, greater understanding of
genomic factors could pave the way for investigations into gene-environment interactions, with
attendant improvements in lifestyle advice delivered to this population. To accomplish these
goals, research on genomic samples from subjects of African ancestry should be dramatically
increased.
We have examined Hilliard’s recently proposed hypothesis of ancestral TRPV6 as a genetic
factor in racial cancer disparities due to excessive cytosolic Ca2+ when calcium consumption is
high. A synthesis of recent discoveries in TRPV6 structure/function/evolution and association of
increasing calcium intake with a pattern of increase in high risk prostate cancer in AA men
supports her hypothesis and leads us to suggest a mechanism for it. Hilliard’s hypothesis, if true,
would imply a rethinking of current dietary advice delivered to people of African ancestry, and
should be investigated via research into the impact of TRPV6 haplotype on prostate, triple
negative breast and other carcinomas from which people of African ancestry suffer
disproportionately. However, to our knowledge, no studies have been conducted to investigate
the association of the TRPV6 ancestral haplotype with cancer, whether as a main effect or in
interaction with another gene or an environmental factor, such as calcium intake. If such research
were to uncover an association of the ancestral TRPV6 haplotype with cancer in people of
African descent, this could lead to precision medicine inclusive of precision prevention:
delivered through improved cancer risk assessment and dietary recommendations specific to the
ancestral genotype.
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